Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

Orly Haskin; Yafa Falush; Miriam Davidovits

doi:10.1007/s00467-019-04341-4

Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

Orly Haskin^*, Yafa Falush, Miriam Davidovits

^*Corresponding author for this work

Schneider Childrens Medical Center Israel

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery. Case-diagnosis/treatment: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis. Conclusion: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.

Original language	English
Pages (from-to)	2601-2604
Number of pages	4
Journal	Pediatric Nephrology
Volume	34
Issue number	12
DOIs	https://doi.org/10.1007/s00467-019-04341-4
State	Published - 1 Dec 2019

Keywords

Child
Dialysis
Eculizumab
aHUS

Access to Document

10.1007/s00467-019-04341-4

Cite this

@article{51c8f40407ca41caaa856732742740b9,

title = "Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature",

abstract = "Background: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery. Case-diagnosis/treatment: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis. Conclusion: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.",

keywords = "Child, Dialysis, Eculizumab, aHUS",

author = "Orly Haskin and Yafa Falush and Miriam Davidovits",

note = "Publisher Copyright: {\textcopyright} 2019, IPNA.",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s00467-019-04341-4",

language = "אנגלית",

volume = "34",

pages = "2601--2604",

journal = "Pediatric Nephrology",

issn = "0931-041X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "12",

}

TY - JOUR

T1 - Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

AU - Haskin, Orly

AU - Falush, Yafa

AU - Davidovits, Miriam

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery. Case-diagnosis/treatment: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis. Conclusion: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.

AB - Background: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery. Case-diagnosis/treatment: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis. Conclusion: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.

KW - Child

KW - Dialysis

KW - Eculizumab

KW - aHUS

UR - http://www.scopus.com/inward/record.url?scp=85073788307&partnerID=8YFLogxK

U2 - 10.1007/s00467-019-04341-4

DO - 10.1007/s00467-019-04341-4

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 31520126

AN - SCOPUS:85073788307

SN - 0931-041X

VL - 34

SP - 2601

EP - 2604

JO - Pediatric Nephrology

JF - Pediatric Nephrology

IS - 12

ER -

Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this